ASCO Annual Meeting | Conference

Bendamustine Superiority in Lymphoma Regimen Confirmed

June 3rd 2012

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.

With Continuous Hormonal Therapy, Certain Men With Prostate Cancer Get Marked Boost in Survival

June 3rd 2012

Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.

Dr. Pujade-Lauraine on the AURELIA Bevacizumab Trial

June 2nd 2012

Dr. Eric Pujade-Lauraine, from UniversitÃ© de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

Dr. Topalian on the PD-1 Targeted Therapy BMS-936558

June 2nd 2012

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

Avastin Delays Disease Progression in Platinum-Resistant Ovarian Cancer

June 2nd 2012

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

Patients With Metastatic Kidney Cancer Prefer Pazopanib Over Sunitinib, Study Shows

June 2nd 2012

Study finds that more than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib.

Large Study of ALL Patients Finds Lower Survival in Adolescent and Young Adult Patients

June 2nd 2012

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

PD-1 Immunotherapy Makes Strong Showing in Three Tumor Types

June 2nd 2012

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

Dr. Rotkowitz on BRAF/MEK Combination Side Effects

June 1st 2012

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

Analysts, Companies Highlight Key ASCO Research

June 1st 2012

Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.

2012 ASCO Pre-Meeting Video Coverage

May 31st 2012

American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.

Advanced Coverage Recap: 2012 ASCO Annual Meeting

May 30th 2012

On May 16, the ASCO highlighted the results of five ground-breaking studies in advance of its annual meeting held in Chicago from June 1-5, 2012.

Dr. Goy Highlights Research From the 2012 ASCO Meeting

May 30th 2012

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

Dr. Gomella on the Unique Attributes of Neoadjuvant Zytiga

May 30th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.

Dr. Markman on Long-Term Chemotherapy Side Effects

May 29th 2012

Dr. Maurie Markman, from Cancer Treatment Centers of America, on Awareness of Long-Term Chemotherapy Side Effects

Dr. Goy on Neoadjuvant Hormonal Therapy Plus Zytiga

May 18th 2012

Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga

Dr. Rotkowitz on the Dabrafenib/Trametinib Combination

May 17th 2012

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma

Neoadjuvant Zytiga Helps Eliminate Some Patients' Prostate Tumors

May 16th 2012

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations

May 16th 2012

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Olanzapine Proves Effective in Breakthrough CINV

May 16th 2012

Olanzapine, an antipsychotic medication that is often used off-label, has proved highly effective in controlling breakthrough chemotherapy-induced nausea and vomiting.